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ABSTRACT 
Acetaminophen (paracetamol, APAP) is a widely used analgesic and antipyretic 
drug safe at therapeutic doses but its overdose causes liver injury. Our goal was to 
explore whether protein tyrosine phosphatase 1B (PTP1B), a negative modulator 
of survival signaling pathways, plays a role in APAP-induced cell death in 
hepatocytes. Hepatotoxicity was evaluated in immortalized hepatocytes 
generated from wild-type (PTP1B+/+) and PTP1B-deficient (PTP1B-/-) mice. 
Apoptosis occurred as an early event only in APAP-treated PTP1B+/+ hepatocytes. 
PTP1B deficiency conferred protection against cell cycle arrest and loss of cellular 
viability. These data suggest that PTP1B as a target against APAP-induced liver 
failure. 
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RESUMEN 
La inhibición de la proteína tirosina fosfatasa 1B protege frente a la apoptosis 
temprana inducida por paracetamol en hepatocitos 
El paracetamol es un analgésico/antipirético hepatotóxico a dosis altas. 
Investigamos el papel de la proteína tirosina fosfatasa 1B (PTP1B), un modulador 
negativo de señalización de supervivencia celular, en la muerte celular temprana 
(apoptosis) inducida por paracetamol en hepatocitos. En hepatocitos controles se 
inducía apoptosis en respuesta al paracetamol. Este efecto se encontraba 
disminuido en hepatocitos deficientes en PTP1B. La falta de PTP1B protegía a los 
hepatocitos de la parada del ciclo celular y la pérdida de la viabilidad celular tras 
el tratamiento con paracetamol. Proponemos a la PTP1B como diana terapéutica 
frente al fallo hepático inducido por sobredosis de paracetamol. 
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Acetaminophen (APAP) or Paracetamol is a widely used analgesic and 
antipyretic drug safe at therapeutic doses (1). However, an accidental or 
intentional overdose can induce severe hepatotoxicity in both experimental 
animals and humans (2). The first reports of APAP hepatotoxicity in humans 
appeared in the literature in the 1960s. In fact, APAP overdose is the most frequent 
cause of drug-induced liver failure in the United States and in Great Britain at 
present (3). Therefore, APAP-induced acute toxicity has become an essential model 
for studying drug-induced liver and kidney failure. In the liver, APAP overdose 
produces a centrilobular hepatic necrosis that can be fatal and is increasingly 
recognized as a significant public health problem (4-6). Moreover, APAP overdose 
is also the second leading cause of liver transplantation, which accounts for 
considerable levels of morbidity and mortality (7). 
 APAP is commonly used for the relief of minor pains like headaches and in 
combination with opioid analgesics is also used in the management of more severe 
pains in advanced cancer and in post-operative periods. While APAP has analgesic 
and antipyretic properties comparable to those of aspirin, its anti-inflamatory 
effects are weak. The mechanisms underlying APAP-induced liver injury have been 
studied for several decades and excellent recent reviews have revealed the main 
cellular and molecular pathways involved in its toxic response (8-12). However, 
despite of substantial progress in our understanding of APAP-induced 
hepatotoxicity, additional mechanisms responsible of the cellular damage induced 
by this drug remain still unknown.  
The initial step in APAP-mediated toxicity is initiated by cytochrome P-450 
(CYP) by a direct two electron oxidation of APAP, a previously unrecognized 
mechanism of CYP P450-mediated reactions, that convert APAP to the reactive 
metabolite N-acetyl-p-benzoquinone imine (NAPQI) causing glutathione (GSH) 
depletion and covalent binding to hepatic parenchymal cell proteins and DNA (13). 
The CYP isoforms important in APAP metabolism are CYP2E1, CYP1A2, CYP3A4 
and CYP2D6 (14-15). Moreover, generation of reactive oxygen (ROS) and nitrogen 
species, lipid peroxidation, mitochondrial dysfunction, disruption of calcium 
homeostasis and induction of apoptosis and necrosis are also involved in APAP-
induced hepatotoxicity (16). 
At therapeutic doses, NAPQI is efficiently detoxified by GSH and eliminated 
in the urine or bile as APAP–cysteine, APAP–N-acetylcysteine (APAP–NAC), and 
APAP–glutathione (APAP–GSH). After an overdose of APAP, the glucuronidation 
and sulfation routes become saturated and more extensive bioactivation of the 
drug occurs leading to rapid depletion of the hepatic GSH pool. Subsequently, 
NAPQI binds to cysteine groups on cellular proteins forming APAP-protein adducts 
(17). Of note, NAPQI also binds to a number of mitochondrial proteins (9-10) 
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which, in turn, causes oxidative stress that may trigger signaling pathways through 
mitochondrial toxicity ultimately leading to lethal cell injury. 
As stated above, the precise mechanisms by which APAP mediates 
hepatotoxicity in both humans and experimental animals still remain to be 
elucidated. Metabolic activation of APAP and NAPQI binding to target proteins and 
DNA seem to be necessary but are not sufficient for toxicity. Recent findings 
indicate that a combination of mitochondrial oxidative stress, increased calcium 
levels and other factors may trigger the mitochondrial membrane permeability 
transition (MPT) pore opening resulting in the collapse of the transmembrane 
potential and then osmotic swelling. These events ultimately cause the rupture of 
the outer mitochondrial membrane and release of cytochrome c and other pro-
apoptotic factors into the cytosol (18). 
Regarding the signaling pathways mediated by various growth factors and 
hormones committed in the regulation of cellular metabolism, differentiation, 
growth and survival, protein tyrosine phosphorylation constitutes a key element. 
Given the importance of tyrosine kinase signaling in maintaining birth and death 
rates of cells, these pathways must be regulated carefully. Protein tyrosine 
phosphatases (PTPs) catalyze the dephosphorylation of tyrosine-phosphorylated 
proteins (19) and are known to be important negative regulators of growth factor 
signaling. Several PTPs have been described which may participate in modulating 
the balance between survival and cell death. Among them, protein tyrosine 
phosphatase 1B (PTP1B) is a widely expressed non-receptor PTP that is associated 
with the endoplasmic reticulum (ER) and other intracellular membranes via a 
hydrophobic interaction of its C-terminal targeting sequence (20). In particular, 
PTP1B dephosphorylates and inactivates receptors belonging to the tyrosine 
kinase superfamily such as the EGF receptor (EGFR) (21), the PDGFR (22), the 
insulin receptor (IR) (23) and the IGF-IR (24), all of them implicated in the survival 
of hepatocytes (25-26) and many other cellular models. Thus, PTPs represent 
novel molecular targets for the development of medicinal reagents that possess 
distinct modes of action. 
During the last years, our laboratory has been interested in the study of key 
proteins that mediate survival pathways in hepatocytes. In this regard, the precise 
role of PTP1B in these processes has been investigated in a study published by 
Gonzalez-Rodriguez et al. (27) which was performed in immortalized neonatal 
hepatocyte cell lines from wild-type (PTP1B+/+) and PTP1B-deficient (PTP1B-/-) 
mice. These cell lines have been proven to be excellent tools for in vitro studies of 
cell death/survival because they express endogenous pro- and anti-apoptotic 
proteins at levels comparable to the liver and hepatocytes of neonatal mice. Using 
these cell lines it was demonstrated that the lack of PTP1B protects against 
apoptosis induced by trophic factors withdrawal, whereas increased expression of 




this phosphatase sensitizes neonatal hepatocytes to death signals induced by this 
apoptotic stimulus (27). These differential effects resulted from the regulation of 
multiple events involving mitochondrial integrity, the Bcl-2 protein family, the 
caspases-8,-9 and -3 and the nuclear translocation of Foxo 1 which activates the 
death receptor pathway. Thus, these previous observations suggested that levels of 
PTB1B may exert a pivotal role in maintaining the balance between survival and 
death in hepatocytes.  
On that basis, the main goal of the present study is to investigate if PTP1B 
deficiency is able to protect hepatocytes against the early events during APAP-
induced hepatotoxicity.  
2. MATERIALS AND METHODS 
2.1. Materials. 
Fetal serum (FS) and culture reagents were obtained from Invitrogen. APAP 
was purchased from Sigma (Sigma-Aldrich).  Anti-phospho-JNK (#9251) (Thr183/ 
Tyr185) and anti-active caspase 3 (#9661) antibodies were from Cell Signaling 
Technology. The antibodies against phospho-Akt (Ser 473) (sc-7985), phospho-
IGF-IR (Tyr 1165/1166) (sc-101704) and total JNK (sc-571) were from Santa Cruz 
Biotechnology. The anti-IRS-1 (06-248), anti-IRS-2 (06-248) and anti-mouse 
PTP1B (07-088) antibodies were obtained from Upstate (Millipore). Anti-BclxL 
(610211) antibody was from BD Pharmingen. Anti-β-actin (A-5441) antibody was 
from Sigma. Anti-Cyp2E1 antibody (aB19140) was from Abcam. Total Akt and total 
IGF-IR antibodies were gifts from M Birnbaum and MF White, respectively (Joslin 
Diabetes Center, USA). Anti GCLc and GCLm antibodies were a gift from T 
Kavanagh (University of Washington, USA). 
2.2. Human liver biopsies. 
Human liver samples were obtained from from five patients intoxicated 
with APAP and three healthy subjects.  These samples were kindly donated from 
Dr Kenneth J. Simpson in the division of Clinical and Surgical Sciences, University 
of Edinburgh, Edinburgh EH164TJ, UK. Informed written consent was obtained 
from each patient.  
2.3. Animal models. 
Three months-old male PTP1B+/+ (wild-type) and PTP1B-/- mice maintained 
on the C57Bl/6J x 129Sv/J genetic background (28) were used throughout the 
study. Animal experimentation was conducted accordingly to the accepted 
guidelines for animal care of the Comunidad de Madrid (Spain). Overnight fasted 
mice were intraperitoneally (i.p.) injected with 500 mg/kg APAP dissolved in 
physiological saline. Mice were sacrificed at 6 h and livers were collected.  
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2.4. Liver histology.  
Histological grading of hepatic necrosis was performed by two blinded 
oervbsers using hematoxilin and eosin (H&E)-stained sections as follows: 30% of 
the total area necrotic (1 point); 30–60% of the total area necrotic (2 points); 60% 
of the total area necrotic (3 points). 
2.5. Generation of immortalized hepatocyte cell lines.  
The detailed protocol for the generation of immortalized neonatal 
hepatocytes from wild-type and PTP1B-/- mice is described in (27). For re-
expression of PTP1B in deficient cells, PTP1B-/- neonatal hepatocytes were 
reconstituted with retroviral Myc-tagged PTP1B (kindly provided by M. L. 
Tremblay, McGill Cancer Center, Quebec, Canada) and four pools of infected cells 
were selected with hygromycin B (200 μg/ml) for 2 weeks. As a control, PTP1B-/- 
were infected with an empty vector (pBabe hygro). The expression of PTP1B in the 
different cell lines was assessed by Western blot. 
2.6. Isolation and culture of primary mouse hepatocytes.  
Mouse hepatocytes were isolated from male mice (8-12 weeks-old) by 
perfusion with collagenase and cultured as described (27). 
2.7. PTP1B immunohistochemistry.  
PTP1B expression was analyzed by immunohistochemistry in human liver 
samples as previously described (29). 
2.8. Determination of Reactive Oxygen Species (ROS).  
Cellular ROS were quantified by flow cytometry using the dichlorofluorescin 
(DCFH) probe.  APAP-stimulated cells were detached by trisinization and collected 
by centrifugation at 2.500 x g for 4 min. Then, cells were washed and resuspended 
in 500 microliters of PBS. DCFH (10 μM) and propidium iodide (0,002% w/v) were 
added 10 min before measurement. Fluorescence was measured with 488-nm 
laser excitation and 510-nm for emission. 
2.9. Analysis of caspase-3 activity.  
At the end of the treatments, cells were scraped off, collected by 
centrifugation at 2.500 x g for 5 min and lysed at 4ºC in 5 mM Tris/HCl pH 8, 20 
mM EDTA, 0,5% Triton X-100. Lysates were clarified by centrifugation at 13.000 x 
g for 10 min. Reaction mixtures contained 25 microliters of cell lysate, 325 
microliters of assay buffer (20 mM HEPES pH 7.5, 10% glycerol, 2 mM 
dithiothreitol) and 20 µM caspase-3 substrate (Ac-DEVD-AMC). After 2-hour 
incubation at 37ºC in the dark, enzymatic activity was measured in a luminescence 
spectrophotometer (Perkin Elmer LS-50, Norwalk, CT) (  excitation, 380 nm;  
emission, 440 nm). We define a unit of caspase-3 activity as the amount of active 
enzyme necessary to produce an increase in 1 arbitrary unit in the fluorimeter 




after 2-hour incubation with the reaction mixture. Protein concentration of cell 
lysates was determined and the results are presented as caspase-3 
activity/micrograms of total protein. 
2.10. Cell viability and cytotoxicity.  
Cell viability/damage was determined by two alternative methods: gross 
detection of cell viability by using the crystal violet assay (30) and cytotoxicity 
assay by measuring lactate dehydrogenase (LDH) leakage into the extracellular 
medium (31). For the crystal violet assay, cells were seeded at low density (104 
cells per well) in 24-well plates, grown for 12 hours with the different treatments 
and incubated with crystal violet (0.2% in ethanol) for 20 min. Plates were rinsed 
with distilled water and allowed to dry and 1% SDS was then added. The 
absorbance of each well was measured using a microplate reader at 570 nm (Bio-
Tek, Winooski, VT, USA). Cytotoxicity was evaluated by the LDH method collecting 
both the culture medium and cells that were scraped in phosphate-buffered saline 
(PBS) after the different treatments. Then, cells were sonicated to ensure breaking 
down the cell membrane to release the total amount of LDH followed by 
centrifugation (1.000 ×g 15 min) to clear up the cell sample. 11 microliters of 
extract were placed into a well of a 96-multiwell system for the assay. In the same 
manner, 11 microliters of each culture medium sample were also deposited in each 
96-multiwell. The LDH leakage was estimated from the ratio between the LDH 
activity in the culture medium and that of the whole cell content. Fluorescence was 
measured at an emission wavelength of 460 nm and an excitation wavelength of 
340 nm. 
2.11. Quantification of apoptotic cells by flow cytometry.  
After APAP stimulation, adherent and non-adherent cells were collected by 
centrifugation, washed with PBS and fixed with cold ethanol. The cells were then 
washed, resuspended in PBS, and incubated with RNAse A (25 µg/106 cells) for 30 
min at 37ºC. After addition of 0.05% propidium iodide, cells were analyzed by flow 
cytometry. 
2.12. Analysis of alanine amino transaminase (ALT) activity.  
Blood was collected in tubes containing heparin and diluted 1/30 with 
saline (0.9% NaCl). ALT activity was determined by direct measurement with the 
Reflotron test (Ref. 10745120, Roche Diagnostics). 
2.13. Protein determination.  
Protein determination was performed by the Bradford dye method, using 





2.14. Western blot analysis.  
To obtain total cell lysates, cells from supernatants were collected by 
centrifugation at 2.000 x g for 5 min at 4ºC. Attached cells were scraped off in ice-
cold PBS, pelleted by centrifugation at 4.000 x g for 10 min at 4ºC and resuspended 
in lysis buffer (25 mM HEPES, 2.5 nM EDTA, 0.1% Triton X-100, 1 mM 
phenylmethylsulfonyl fluoride and 5 µg/ml leupeptin). Cellular lysates were 
clarified by centrifugation at 12.000 x g for 10 min. After SDS-PAGE, gels were 
transferred to Immobilon membranes (Millipore), blocked using 5% non-fat dried 
milk or 3% bovine serum albumin (BSA) in 10 mM Tris-HCl, 150 mM NaCl pH 7.5 
(TBS) and incubated overnight with antibodies as indicated in 0.05% Tween-20-
TBS. Immunoreactive bands were visualized using the ECL Western blotting 
protocol (Millipore). 
2.15. Statistical Analysis.  
The data are expressed as means ± SD. The statistical significance was 
estimated with Student's test for unpaired observation (p*<0.05;  p**<0.01; and  
p***<0.001). 
3. RESULTS AND DISCUSSION 
PTP1B expression is induced in human liver during APAP intoxication.  
Cell proliferation and cell death are governed by stimulatory and inhibitory 
signals. Whereas trophic factors simultaneously stimulate mitosis and inhibit cell 
death, negative growth signals regulate the opposite of these biological effects. In 
the liver, trophic factors include endogenous growth factors such as EGF, bFGF, 
TGF-alpha and IGFs that act through receptors belonging to the tyrosine kinase 
superfamily (32). Thus, tyrosine phosphorylation may play a regulatory role in the 
induction and execution of programmed cell death in the liver. On that basis, our 
first goal in this work was to investigate whether an overdose of APAP induced the 
expression of PTP1B, a negative modulator of survival-mediated signaling 
pathways, in human liver biopsies obtained from individuals suffering from APAP 
intoxication. In our previous work (33) we showed elevated PTP1B expression in 
patients with APAP toxcicity that needed liver tranplantion. In agreement with 
this, Figure 1 shows elevated PTP1B expression in another patient suffering from 
APAP intoxication. Notably, immunostaining was detected  in surviving 
hepatocytes in the areas surrounding the central veins (right panel) as compared 
to a normal liver (left panel).  
PTP1B deficiency protects mouse hepatocytes against elevation of ROS.  
The fact that PTP1B has been related to the induction of apoptosis in 
hepatocytes under conditions of serum withdrawal (27) or activation of the Fas 
death receptor (34) prompted us to investigate the involvement of PTP1B in the 




susceptibility of hepatocytes to undergo apoptotic cell death induced by APAP. As 
indicated in the introduction section, APAP overdoses cause severe hepatotoxicity 
leading to liver failure in experimental animals and humans. APAP hepatotoxicity 
is, in part, the result of a series of events that increase cellular oxidative stress. In 
the liver, Cyp2e1 converts APAP to NAPQI that rapidly depletes GSH and the 
subsequent generation of ROS (7), and therefore the degree of GSH consumption is 
a biomarker for APAP bioactivation (35). Both the catalytic and the modifier 
subunits of γ-glutamyl cysteine ligase (GCL-C and GCL-M) are responsible for 
glutathione synthesis. Since the expression of Cyp2e1, GCL-C and GCL-M did not 
change in primary and immortalized hepatocytes from both genotypes of mice 
(Figure 2A), we used immortalized cells for further experiments. 
 
Figure 1.-PTP1B expression is increased during APAP-induced liver injury. Representative 
anti-PTP1B immunostaining of liver biopsy sections from an individuals with histologically normal 
liver (NL) or with APAP overdose intoxication (APAP).  Bar scale 50 µm. 
  
It has been extensively reported that APAP hepatotoxicity concurs with 
elevated ROS (36). To evaluate the degree of cellular oxidative stress in APAP-
treated hepatocytes, the intracellular ROS production was estimated. Figure 2B 
shows a representative plot with the shift of the mean fluorescence after APAP 
treatment for 6 h at 0.5 and 1 mM concentrations in immortalized hepatocytes. 
Importantly, ROS production was significantly ameliorated in hepatocytes lacking 
PTP1B compared to the wild-type controls.  
Programmed cell death (apoptosis) induced by APAP treatment involves 
activation of caspase-3: protective effect of PTP1B deficiency.  
To further investigate whether caspase-3 is involved in APAP-induced 
apoptosis, we examined caspase-3 activity in wild-type and PTP1B-/- immortalized 
hepatocytes. Cells were treated with APAP in a dose-dependent manner and 
caspase-3 enzymatic activity was analyzed as described in Materials and Methods. 
As shown in Figure 3A, caspase-3 activity increased with APAP treatment for 8 h in 
wild-type hepatocytes with a maximal effect at 1 mM concentration. However, in 
the absence of PTP1B, hepatocytes were protected against activation of caspase-3 




Figure 2.- Effects of PTP1B deficiency in APAP-mediated effects in oxidative stress in 
hepatocytes. A. Whole cell lysates from PTP1B+/+ and PTP1B-/- mouse
 
primary (left panel) and 
immortalized (right panel) hepatocytes were analyzed by Western blot with the indicated 
antibodies. Representative autoradiograms are shown. B. Analysis of ROS levels in APAP-treated 
wild-type and PTP1B-/- immortalized hepatocytes for 6 h. Representative plots with the shift of the 
mean fluorescence after APAP treatment are shown. 
 
Caspases are synthesized as inactive zymogens, whose cleavage represents 
its activation (37). Accordingly, we examined the presence of the active fragment 
of caspase-3 (15-17 kDa) by Western blot analysis. As shown in Figure 3B, a 
marked increase in active caspase-3 fragment was observed in APAP-treated wild-
type immortalized hepatocytes for 8 h in a dose-dependent manner. However, in 
PTP1B-/- cells this effect was ameliorated. Importantly, at this early time point we 
could not see any decrease in the cellular viability as assessed by crystal violet 
staining and the analysis of LDH enzymatic activity suggesting that apoptosis is a 
very early event triggered by APAP in hepatocytes (Figure 4A, 4B). 
  





Figure 3.- PTP1B-deficient hepatocytes are protected against APAP-induced caspase-3 
activation. PTP1B+/+ and PTP1B-/- immortalized hepatocytes were treated with various doses of 
APAP for 8 h. A. Analysis of caspase-3 enzymatic activity. B. Analysis of the active caspase-3 
fragment in total cell lysates by Western blot. *P<0.05 and ***P<0.005 PTP1B-/- vs. PTP1B+/+ cells 
(n=4 independent experiments). 
 
Effect of APAP treatment in the cell cycle of wild-type and PTP1B-/- hepatocytes.  
We next investigated the effects of APAP in the distribution of the 
hepatocytes along the phases of the cell cycle including the hypodiploid (sub 
G0/G1) population. In wild-type hepatocytes, APAP treament induced cell cycle 
arrest in S phase with a maximal effect at 0.5 mM dose. Of note, under these 
experimental conditions a twofold increase in the percentage of S phase arrested 
cells was observed  (Figure 5A). This effect was significantly ameliorated in 
hepatocytes lacking PTP1B. We also observed that APAP treatment increased the 
percentage of hypodiploid cells in wild-type hepatocytes, but again this effect was 
significantly reduced in PTP1B-/- hepatocytes (Figure 5B). This result indicates an 





Figure 4.- Immortalized PTP1B-deficient hepatocytes are protected against APAP-induced 
cell death.  PTP1B+/+ and PTP1B-/- immortalized hepatocytes were treated with various doses of 
APAP for 8 h. Cellular viability (A) and released LDH activity (B) were analyzed. *P<0.05, **P<0.01 
and ***P<0.005 PTP1B-/- vs. PTP1B+/+ hepatocytes (n=4 independent experiments). 
 
Cell death (irreversible loss of vital cellular structure and function) is a 
fundamental phenomenon of biological organisms. Several lines of investigation 
have led to the concept that there are two fundamental types of cell death: 
apoptosis and necrosis. The findings of our study demonstrated that the 
administration of APAP at  heptotoxic doses led to  the induction of cell death by 
both necrosis and apoptosis, with apoptotic cell death typically preceeding 
necrosis. Therefore, we analyzed the population of  apoptotic and necrotic cells in 
response to APAP by flow cytometry. The results shown in Figure 6 and Table 1 
indicate a protection against both types of cell death in response to APAP in 
PTP1B-/- hepatocytes as compared to wild-type cells. 
Effect of APAP treatment in the signaling pathways that modulate cell death 
and survival in wild-type and PTP1B-deficient hepatocytes.  
At the molecular level, we analyzed both stress-mediated and survival 
signaling in wild-type and PTP1B-/- hepatocytes upon APAP treatment. The c-Jun 
N-terminal Kinases (JNKs), a subfamily of the mitogen-activated protein (MAP) 
kinases, have been shown to be activated by phosphorylation at early time-periods 
after APAP treatment in hepatocytes (38-39). To analyze JNK activation in 
immortalized hepatocytes, cells were treated with different doses of APAP for 8 h 
and JNK phosphorylation was examined by Western blot analysis. As shown in 




Figure 7A, APAP markedly increased the levels of phosphorylated JNK in wild-type 
hepatocytes. Interestingly, the lack of PTP1B prevented JNK activation in response 
to APAP. 
 
Figure 5.- PTP1B-deficient hepatocytes are protected against APAP-induced arrest in the S 
phase of the cell cycle. A. PTP1B+/+ and PTP1B-/- immortalized  hepatocytes were treated with 
various doses of APAP for 16 h. The percentage of S phase cell population was measured by flow 
cytometry.  B. Images of flow cytomerty showing the effect of APAP treatment on  G0/G1 and S 
phases in both PTP1B+/+ and PTP1B-/- immortalized  hepatocytes. *P<0.05, **P<0.01 and 
***P<0.005 PTP1B-/- vs. PTP1B+/+ cells (n=4 independent experiments). 
 
Table 1.-  Effect of APAP treatment in the induction of both apoptosis and necrosis in PTP1B+/+ 
PTP1B-/- hepatocytes. 
Population PI PI+* PI+dim** 
PTP1B
+/+
  C 99.5 10 10.8 
PTP1B
+/+
  0.5mM 98.5 22.7 24.1 
PTP1B
+/+
  1mM 98.7 23.1 24.6 
PTP1B
-/-
   C 99.9 4.5 3.9 
PTP1B
-/-
   0.5mM 99.5 7.2 5.7 
PTP1B
-/-






Figure 6.- PTP1B-deficient hepatocytes are protected against APAP-induced apoptosis and 
necrosis. PTP1B+/+ and PTP1B-/- immortalized  hepatocytes were treated with various doses of 
APAP for 16 h. Apoptosis and necrosis was measured by PI staining by flow cytometry (n=4 
independent experiments). 
 
To study the effect of APAP on the survival signaling pathways, 
phosphorylation of the IGF-IR, levels of IRS1 and activation of Akt were examined. 
As depicted in Figure 7B, phosphorylation of the IGF-IR and its downstream target 
Akt decreased in APAP-treated wild-type hepatocytes at 8 h, but it was maintained 
along APAP treatment in PTP1B-deficient hepatocytes. These results  indicate that 
the protective effect of PTP1B deficiency also involve the increase in survival 
signaling. Interestingly, in PTP1B-deficient hepatocytes IRS1 degradation induced 
by APAP was attenuated. Alltogether these results suggest that the increased 
tyrosine phosphorylation of IGF-IR as a result of PTP1B deficiency elicits 
hepatoprotection in conjunction with the attenuation of stress-mediated signaling. 
Bcl-xL is a member of the Bcl-2 family with anti-apoptotic properties (40-
41). On that basis, we analyzed the expression of Bcl-xL after 8 h of APAP 
treatment in wild-type and PTP1B-/- hepatocytes. As shown in Figure 7C, wild-type 
cells showed a decrease in the expression of BclxL after APAP treatment whereas 
BCLxL expression was maintained in hepatocytes lacking PTP1B.  





Figure 7.- Effect of PTP1B deficiency in stress and survival signaling in hepatocytes. PTP1B+/+ 
and PTP1B-/-   immortalized hepatocytes were treated with various doses of APAP for 8 h. Total cell 
lysates were analyzed by Western blot with the antibodies against phospho-JNK1/2 and JNK1/2 
(A), phosphor-IGFIR, IGFIR, IRS1, phospho-Akt and Akt (B) and  BclxL and β-actin as a loading 
control (C). Representative autoradiograms corresponding to three independent experiments are 
shown. D. PTP1B-/- immortalized hepatocytes were reconstituted  with PTP1B by retroviral gene 
transfer. PTP1B-/- and PTP1B-/-Rec cells were treated with various doses of APAP for 16 h. Total cell 
lysates were analyzed by Western blot with the indicated antibodies. Representative 
autoradiograms corresponding to three independent experiments are shown. 
 
Our next step was to study the effect of PTP1B reconstitution of PTP1B-
deficient hepatocytes in the signaling pathways modulated by APAP. For this goal, 
we reconstituted PTP1B expression in deficient cells by retroviral gene transfer as 
described in Materials and Methods. As a control, hepatocytes were infected with 
an empty retroviral construct. Figure 7D shows the re-expression of PTP1B in 
PTP1B-/- immortalized neonatal hepatocytes (refrerred as PTP1B-/- Rec). 
Importantly, re-expression of recombinant PTP1B in PTP1B-/- neonatal 
hepatocytes induced a decline of IGF-IR phosphorylation after APAP treatment 
similar to the effects observed in wild-type cells. In addition, APAP treatment 
activated JNK phosporylation in PTP1B-/- Rec neonatal hepatocytes as in wild-type 
cells. 
We have recently reported that APAP preotected against liver injury 
induced by a toxic dose of APAP (300 mg/kg) in mice (33). To reinforce this 
finding, we injected both PTP1B+/+ and PTP1B-/- mice with a higher dose of APAP 
(500 mg/kg) and analyzed liver toxicity. Serum ALT was higher in APAP-injected 
wild-type than in PTP1B-/- mice (Figure 8A). Moreover, less injury was observed in 
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liver sections from APAP-injected PTP1B-/- mice as compared to the wild-type 
controls that presented histological signs of severe hepatotoxicity (Figure 8B). 
PTP1B-deficient mice are protected against liver damage induced at a high 
dose of APAP.  
We next determined if reduced sensitivity of PTP1B-/- mice to APAP-
induced liver injury was associated with alterations in basal GSH levels in the two 
mose strains. Interestingly, the basal expression of Cyp2e1, GCL-C and GCL-M and 
basal GSH levels were comparable among both genotypes of mice (Figure 8C, 8D). 
 
Figure 8.- PTP1B-deficient mice are protected against liver damage induced by a high dose of 
APAP under similar GSH levels and expression of Cyp2e1, GCL-C, GCL-M and BclxL in the 
liver. PTP1B+/+ and PTP1B-/- mice were injected with 500 mg/kg APAP or saline for 6 h. A. ALT 
activity.
 **
P<0.01 PTP1B-/- vs. PTP1B+/+ mice (n= 6-8 mice of each condition).  B. Representative 
Hematoxylin & Eosin staining in liver sections. Bar scale 100 µm. C. Basal GSH levels in livers from 
PTP1B+/+ and PTP1B-/- mice. D. Whole cell lysates from both mice +were analyzed by Western blot 
with the indicated antibodies. Representative autoradiograms are shown. 
4. CONCLUSION  
In summary, the present study provides the first molecular evidence that 
levels of PTB1B modulate susceptibility to apoptosis that occurred at early time-
periods in hepatocytes treated with toxic doses of APAP. Thus, our results have 
revealed that PTP1B inhibition might be therapeutically of interest against the 
hepatotoxicity induced by overdoses of APAP. 
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